File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Web of Science: 0
- Appears in Collections:
Conference Paper: Serum Fibronectin Levels Identified Via Proteomics Profiling Predict Spontaneous Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B
Title | Serum Fibronectin Levels Identified Via Proteomics Profiling Predict Spontaneous Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B |
---|---|
Authors | |
Issue Date | 2018 |
Publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/ |
Citation | The Liver Meeting 2018, American Association for the Study of Liver Diseases (AASLD), San Francisco, USA, 9-13 November 2018. Abstracts in Hepatology, 2018, v. 68 n. Suppl. 1, p. 1185A-1186A How to Cite? |
Abstract | Background: Seroclearance of hepatitis B surface antigen (HBsAg) is perceived as the practically ideal treatment endpoint and “functional cure” of chronic hepatitis B (CHB). Our previous analysis of isobaric tags for relative and absolute quantitation (iTRAQ) based proteomics demonstrated HBsAg seroclearance was associated with overexpression of serum fibronectin. In this study, we aimed to validate the predictive value of fibronectin in a large population of CHB patients with HBsAg seroclearance. Methods: We retrieved archived serum samples from our previous study comparing
serum HBsAg kinetics between CHB achieving spontaneous HBsAg seroclearance with age- and sex-matched hepatitis B e antigen (HBeAg)-negative controls. Serum fibronectin levels at 3 years (Year -3) and 1 year (Year -1) before HBsAg seroclearance and at the time of HBsAg seroclearance (Year 0) were assayed using the Human Fibronectin Enzyme-Linked Immunosorbent Assay (ELISA) kit (ab108848,
Abcam). Association of changes between serum fibronectin and HBsAg levels were analyzed. Results: In 139 patients achieving HBsAg seroclearance and with available archived serum, the mean age was 52.3±11.1 years (66.2% male), of which 38 (27.3%) patients had developed anti-HBs. The median HBsAg level in HBeAg-negative control group (n=139) was 2.55 log (interquartile range (IQR): 1.28-3.32)
IU/mL. At Year 0, patients achieving HBsAg seroclearance had lower median HBV DNA levels when compared to controls (1.36±0.21log IU/ml vs. 3.16±1.37 log IU/ml, P<0.001). At both year -1 and year 0, patients who achieved spontaneous HBsAg seroclearance had significantly higher median fibronectin levels than that of the controls (331.57 μg/ml vs. 226.97 μg/ml; 432.02 μg/ml vs. 281.14 μg/ml, both
P <0.001, respectively). The levels of fibronectin at Year -3 were comparable in the two groups. In patients with an annual HBsAg log reduction >1 (n=68), serum fibronectin level at Year -1, when compared to matched controls, achieved an area under the receiving operator characteristic (AUROC) of 0.789 (95% confidence interval [CI]: 0.575-1.000; P=0.038) in predicting HBsAg seroclearance. The optimal cut-off fibronectin level for predicting HBsAg seroclearance was 210.52 μg/ml. Conclusion: Higher serum fibronectin level one year prior to HBsAg seroclearance were associated with subsequent HBsAg seroclearance. Combining serum fibronectin level with the degree of HBsAg reduction may act
as novel predictors for HBsAg seroclearance. Exploration of the pathophysiological role of fibronectin on HBsAg seroclearance is needed in future studies. |
Description | Poster Presentation - no. 2080 |
Persistent Identifier | http://hdl.handle.net/10722/269509 |
ISSN | 2023 Impact Factor: 12.9 2023 SCImago Journal Rankings: 5.011 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Liu, F | - |
dc.contributor.author | Seto, WKW | - |
dc.contributor.author | Wong, DKH | - |
dc.contributor.author | Huang, FY | - |
dc.contributor.author | Mak, LY | - |
dc.contributor.author | Cheung, KSM | - |
dc.contributor.author | Fung, JYY | - |
dc.contributor.author | Lai, CL | - |
dc.contributor.author | Yuen, RMF | - |
dc.date.accessioned | 2019-04-24T08:09:08Z | - |
dc.date.available | 2019-04-24T08:09:08Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | The Liver Meeting 2018, American Association for the Study of Liver Diseases (AASLD), San Francisco, USA, 9-13 November 2018. Abstracts in Hepatology, 2018, v. 68 n. Suppl. 1, p. 1185A-1186A | - |
dc.identifier.issn | 0270-9139 | - |
dc.identifier.uri | http://hdl.handle.net/10722/269509 | - |
dc.description | Poster Presentation - no. 2080 | - |
dc.description.abstract | Background: Seroclearance of hepatitis B surface antigen (HBsAg) is perceived as the practically ideal treatment endpoint and “functional cure” of chronic hepatitis B (CHB). Our previous analysis of isobaric tags for relative and absolute quantitation (iTRAQ) based proteomics demonstrated HBsAg seroclearance was associated with overexpression of serum fibronectin. In this study, we aimed to validate the predictive value of fibronectin in a large population of CHB patients with HBsAg seroclearance. Methods: We retrieved archived serum samples from our previous study comparing serum HBsAg kinetics between CHB achieving spontaneous HBsAg seroclearance with age- and sex-matched hepatitis B e antigen (HBeAg)-negative controls. Serum fibronectin levels at 3 years (Year -3) and 1 year (Year -1) before HBsAg seroclearance and at the time of HBsAg seroclearance (Year 0) were assayed using the Human Fibronectin Enzyme-Linked Immunosorbent Assay (ELISA) kit (ab108848, Abcam). Association of changes between serum fibronectin and HBsAg levels were analyzed. Results: In 139 patients achieving HBsAg seroclearance and with available archived serum, the mean age was 52.3±11.1 years (66.2% male), of which 38 (27.3%) patients had developed anti-HBs. The median HBsAg level in HBeAg-negative control group (n=139) was 2.55 log (interquartile range (IQR): 1.28-3.32) IU/mL. At Year 0, patients achieving HBsAg seroclearance had lower median HBV DNA levels when compared to controls (1.36±0.21log IU/ml vs. 3.16±1.37 log IU/ml, P<0.001). At both year -1 and year 0, patients who achieved spontaneous HBsAg seroclearance had significantly higher median fibronectin levels than that of the controls (331.57 μg/ml vs. 226.97 μg/ml; 432.02 μg/ml vs. 281.14 μg/ml, both P <0.001, respectively). The levels of fibronectin at Year -3 were comparable in the two groups. In patients with an annual HBsAg log reduction >1 (n=68), serum fibronectin level at Year -1, when compared to matched controls, achieved an area under the receiving operator characteristic (AUROC) of 0.789 (95% confidence interval [CI]: 0.575-1.000; P=0.038) in predicting HBsAg seroclearance. The optimal cut-off fibronectin level for predicting HBsAg seroclearance was 210.52 μg/ml. Conclusion: Higher serum fibronectin level one year prior to HBsAg seroclearance were associated with subsequent HBsAg seroclearance. Combining serum fibronectin level with the degree of HBsAg reduction may act as novel predictors for HBsAg seroclearance. Exploration of the pathophysiological role of fibronectin on HBsAg seroclearance is needed in future studies. | - |
dc.language | eng | - |
dc.publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/ | - |
dc.relation.ispartof | Hepatology | - |
dc.relation.ispartof | American Association for the Study of Liver Diseases (AASLD): The Liver Meeting 2018 | - |
dc.title | Serum Fibronectin Levels Identified Via Proteomics Profiling Predict Spontaneous Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.email | Wong, DKH: danywong@hku.hk | - |
dc.identifier.email | Huang, FY: fungyu@hkucc.hku.hk | - |
dc.identifier.email | Cheung, KSM: cks634@hku.hk | - |
dc.identifier.email | Fung, JYY: jfung@hkucc.hku.hk | - |
dc.identifier.email | Lai, CL: hrmelcl@hkucc.hku.hk | - |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.authority | Wong, DKH=rp00492 | - |
dc.identifier.authority | Cheung, KSM=rp02532 | - |
dc.identifier.authority | Fung, JYY=rp00518 | - |
dc.identifier.authority | Lai, CL=rp00314 | - |
dc.identifier.authority | Yuen, RMF=rp00479 | - |
dc.identifier.hkuros | 297385 | - |
dc.identifier.volume | 68 | - |
dc.identifier.issue | Suppl. 1 | - |
dc.identifier.spage | 1185A | - |
dc.identifier.epage | 1186A | - |
dc.identifier.isi | WOS:000446020503308 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 0270-9139 | - |